Lexicon Pharmaceuticals (LXRX) Posts Q3 Loss of 6c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq hits near three-month low as Amazon, Intel deepen AI capex concerns
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $1.43 -3.38%
Revenue Growth %: -79.9%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
BNCC, ZVOI, SYRS, More
Revenue Growth %: -79.9%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
BNCC, ZVOI, SYRS, More
Join SI Premium – FREE
Lexicon Pharmaceuticals (NASDAQ: LXRX) reported Q3 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $372 thousand versus the consensus estimate of $600 thousand.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Why Beijing could block the SpaceX-Tesla merger
- Starz shares jump as Raymond James upgrades to strong buy after earnings
- Iradimed Corp. (IRMD) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
